ProQR Therapeutics NV
NASDAQ:PRQR
ProQR Therapeutics NV
NASDAQ:PRQR
Price:
2.01 USD
1.01%
Market Closed
Updated:
May 5, 2024
ProQR Therapeutics NV
Cash from Financing Activities
|
ProQR Therapeutics NV
Cash from Financing Activities Peer Comparison
Comparables:
PHARM
QURE
ARGX
MRUS
N
NAMS
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Cash from Financing Activities
-€2.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Cash from Financing Activities
-$1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Cash from Financing Activities
$362.7m
|
CAGR 3-Years
266%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
argenx SE
XBRU:ARGX
|
Cash from Financing Activities
$1.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Cash from Financing Activities
$230.1m
|
CAGR 3-Years
80%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Cash from Financing Activities
€375.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ProQR Therapeutics NV's Cash from Financing Activities?
Cash from Financing Activities
-2.3m
EUR
-2.3m
EUR
Based on the financial report for Dec 31, 2023, ProQR Therapeutics NV's Cash from Financing Activities amounts to -2.3m EUR.
What is ProQR Therapeutics NV's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
93%
93%
Over the last year, the Cash from Financing Activities growth was 93%.
You don't have any saved screeners yet
